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patients with ICD-9CM codes for schizophrenia (295.xx). Records were assessed for
a period of 18 months (6-month pre-index period with no antipsychotics plus 12-
month post-index period). A medication possession ratio (MPR) of  80% or a pro-
portion of days covered (PDC) of 80%was considered adherent. RESULTS: A total
of 1,470 patients met inclusion criteria; 31% (n462) had an MPR  80%. Based on
MPR, 30% (405/1338) in the oral cohort and 43% (57/132) in the injectable cohort
were adherent. Logistic regression analyses adjusting for demographic covariates
(age, gender, race) showed that patients in the injectable cohort were about 77%
more likely to be adherent based on MPR (OR1.77, 95% CI1.22-2.56, p0.05)
compared to the oral cohort. Of the demographic covariates, race (Blacks  less
adherent; p0.001) was the only significant covariate. Similarly, increased adher-
ence in the injectable cohort (OR1.81, 95% CI1.24-2.63, p0.05) was also found
using PDC, where race (Blacks less adherent; p0.001) and gender (women less
adherent; p0.05) were significant. CONCLUSIONS: Overall, less than one-third of
all patients were adherent (MPR  80%) one year after their index date. Patients
taking long-acting injectable risperidone had higher rates of adherence compared
to patients taking oral risperidone alone. In addition, this findingwas confirmed by
PDC, which has been shown to be a more conservative calculation of adherence in
patients with schizophrenia.
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OBJECTIVES: To examine the association of antipsychotic adherence with adher-
ence to medications for diabetes, hyperlipidemia, and hypertension and with
healthcare utilization.METHODS:Medstat Medicaid claims data were used to gen-
erate cohorts of patients with schizophrenia newly initiating a second generation
antipsychotic and using medications for diabetes, hypertension, and hyperlipid-
emia. Quarterly (Q) adherence measurements were calculated for each patient to
capture initiation (Q1), continuation (Q2-Q4), andmaintenance (Q5-Q8) periods via
the proportion of days covered (PDC)  80%. Generalized estimating equations
examined the association of initiation period antipsychotic adherencewith comor-
bid medication adherence and health service utilization during the continuation
phase. Similarly, continuation phase antipsychotic adherence was used to predict
parallel maintenance phase outcomes. RESULTS: Patients adherent to antipsy-
chotic treatment during initiation (Q1) were more adherent to medications for
diabetes [Odds Ratio (OR) 1.77; 95% CI(0.95, 3.29)], hypertension [1.36, (0.91, 2.04)],
and hyperlipidemia [2.24, (1.02, 4.90)] during the continuation phase. Similarly,
continuation phase antipsychotic adherence was associated with higher adher-
ence to medications for diabetes [4.99, (2.85, 8.71)], hypertension [7.51, (5.07,
11.12)], and hyperlipidemia [5.68, (2.71, 11.92)] during the maintenance phase.
Higher antipsychotic adherence during the continuation phase also was asso-
ciated with more frequent outpatient visits [Incident Rate Ratio  1.53 (1.21,
1.94), 1.57 (1.35, 1.82), 1.63 (1.28, 2.07)], less frequent inpatient admission [OR 
0.73 (0.43, 1.26), 0.70 (0.49, 1.00), 0.87 (0.49, 1.54)] and less frequent emergency
department use [OR  0.68 (0.42, 1.10), 0.58 (0.47, 0.78), 0.76 (0.47, 1.25)] during
the maintenance phase among patients with diabetes, hypertension, and hy-
perlipidemia respectively. CONCLUSIONS: Antipsychotic adherence was associ-
ated with better adherence to medications for chronic comorbid health conditions
as well as a trend toward lower inpatient and emergency department use over a 2
year period. These findings suggest potential benefits to antipsychotic adherence
beyond mental health management.
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OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is an effec-
tive treatment for OD, but is hypothesized to have the greatest impact on those
patients who are compliant. This analysis was conducted to compare economic
costs and benefits between B-MAT compliant and non-compliant OD members.
METHODS: A longitudinal, multivariate analysis was conducted using service use
claims data among a sample of Aetna members with full benefit coverage and at
least one diagnoses of OD during the 48monthmeasurement period (Q1 2006 to Q4
2009). Medication possession ratio (MPR) was calculated for the sample (n  725).
Memberswith anMPR .80were classified as compliant (n 324), with the balance
classified as non-compliant (n  401). Two six-month measurement periods were
constructed around the index date. RESULTS: After B-MAT induction, compared to
non-compliant B-MATmembers, compliantmembers increased their total number
of prescriptions filled by an average of 2.57 per member (P  0.007). However,
B-MAT compliant members showed decreases in inpatient hospital admissions
(0.62), inpatient hospital days (4.77), and emergency room visits (0.42; P’s
0.001). Concerning healthcare costs, compliant B-MAT members increased their
spend at the pharmacy compared to non-compliant B-MATmembers by $1,059 per
member (P  0.001), but decreased inpatient hospital costs ($9,623) and ER costs
($1,068; P’s  0.001). Overall, compliant B-MAT members spent a total of $14,448
less (P 0.001) per member over the first six months of treatment. CONCLUSIONS:
Though compliant B-MAT patients incur higher pharmacy and costs, they use
fewer expensive health care services in other areas, resulting in an overall positive
cost-benefit conclusion for B-MAT. Compliance with medication-assisted treat-
ment is essential for patient recovery, but given that less than half of the sample
had an MPR  .80, additional treatment ancillaries or disease management pro-
grams may be needed to increase patient compliance.
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OBJECTIVES:Bipolar Disorder (BP) is a condition inwhich adherence to therapy and
medication is vital to help patients avoid severe social and emotional problems.
Patient beliefs are one of many important factors that determine patient adher-
ence.We sought to systematically review the literature on the role of patient beliefs
about their BP, their medications, and their health care team, and the impact these
beliefs have on adherence to both medication and therapy.METHODS: A system-
atic literature review was performed using Medline, PubMed and PsychInfo. The
eligibility criteria for studies were as follows: studies published from January 1,
2000 through March 28, 2010; patient sample comprised BP patients only; adher-
ence to either medication or therapy was a primary study outcome; measures of
patient beliefs or belief system were reported. Titles and abstracts were screened
for potentially relevant studies. RESULTS: A total of 10 studies met our study in-
clusion criteria; study participants usually consisted of BP patients recruited from
outpatient clinics and similar sites. A wide variety of beliefs ranging from disease
denial, doubt ofmedication efficacy, fear of side effects, desire for alternative treat-
ment, and conflicting religious ideas all had a negative impact on adherence to
medication and therapy. A strong patient-provider relationship, belief that medi-
cation was necessary, and belief that benefits outweighed risks were identified as
beliefs that positively impacted patient adherence.CONCLUSIONS:Themajority of
primary literature on BP patient beliefs and adherence focuses mostly around the
patient-provider relationship, and concerns aboutmedication side effects. There is
a lack of studies that deal with other patient beliefs such as how they feel about
their diagnosis, their belief in medication efficacy, and how their spiritual beliefs
affect adherence. A better understanding of patient beliefs may help improve cli-
nicians’ counseling techniques, and help them to encourage greater adherence to
medication and therapy.
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OBJECTIVES:The Illness PerceptionQuestionnaire (IPQ)was designed as ameasure
of illness perception and has been adapted on many occasions for use in distinct
domains. More recently modified versions of the IPQ have been used to determine
the illness perceptions of people with schizophrenia and their carer’s. The current
investigation examined the utility of a modified version of the IPQ to assess
changes in mental health practitioners’ illness perceptions about schizophrenia
after completing postgraduate training in psychosocial interventions. METHODS:
A total of 245 mental health practitioners completed a modified version of the IPQ
pre and post training in a psychosocial interventions postgraduate course. The
structure of the questionnaire was evaluated using confirmatory factor analysis
and the internal consistencies of sub-scaleswithin the instrumentwere examined.
RESULTS: Model fit indices revealed a poor fit to the data across all of the models
evaluated (CFI  0.51-0.80, RMSEA  0.12-0.20). Internal consistency analysis re-
vealed a number of sub-scales (0.53-0.78) in the instrument to also have poor psy-
chometric qualities. CONCLUSIONS: The suitability of the modified version of the
IPQ for evaluating the impact psychosocial intervention training on changes in
illness perceptions of schizophrenia in mental health practitioners is not sup-
ported based on psychometric criteria. The need to develop a valid and reliable
measure to assess the illness perceptions of health professionals have of patients
in their care remains a priority.
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OBJECTIVES: This study was undertaken to estimate utility values for alternative
treatment intervals for long acting antipsychotic intramuscular injections for the
treatment of schizophrenia. METHODS: Vignettes were developed using the pub-
lished literature and an iterative consultation process with expert clinicians and
patient representative groups. Four vignettes were developed. The first was a vi-
gnette of relapsed/untreated schizophrenia. The other three vignettes presented a
standardised picture of well managed schizophrenia with variations in the inter-
vals between injections: once every 2weeks, 4-weeks and 3months. The time trade
off (TTO) approach was used to obtain utility values for the vignettes. As a societal
perspective was sought, a representative sample of individuals from across the
community (Sydney, Australia) was recruited. Ninety-eight people completed the
TTO interview. The vignettes were presented in random order to prevent possible
ordering effects. RESULTS: A clear pattern of increasing utility was observed with
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